

# Index

Page numbers in *italics* refer to figures and tables.

- AAPS *see* American Association of Pharmaceutical Scientists
- ABC *see* adenosine triphosphate-binding cassette
- absolute bioavailability 279
- absorption
  - absorption-enhancement 277
  - absorption–lipophilicity
    - correlation 304, 306
  - absorption–partition relationships 306
  - absorptive epithelial cells 117
  - absorptive transporters 193
    - amino acid transporters 195
    - BDDCS 291
    - dipeptides 195, 199
    - drug delivery importance 204
    - epithelial cells 196
    - genes 207
    - hexose transporters 201
    - influx transporters 208
    - intestinal absorption impacts 205
    - intestine 118, 121, 121, 195, 205
    - kidney 195, 208
    - kinetics 207
    - liver 208
    - nucleosides 202
    - nutrients 196
    - organic anion and cation transporters 209
    - organic anion-transporting polypeptides 208
    - peptide transporters
    - solute carrier family 194, 198, 201, 208
    - substrate specificity 207
    - tissue segments 205
    - tripeptides 195, 199
    - vitamins 196, 203
- barrier structure and function 115
  - brain 126
  - colon 118, 123
  - epithelial cells 117
  - epithelial morphology 115
  - eye 129
  - gastrointestinal tissue 118, 121
  - lungs 124
  - nasal cavity 124
  - nose 124
  - oesophagus 118, 119
  - olfactory epithelium 124
  - oral cavity 118, 119
  - pharynx 119
  - pyloric sphincter 118, 121
  - rectum 118, 123
  - respiratory tract 123
  - skin 125
  - small intestine 118, 121
  - tight junctions 117
- BCS 279, 294
- biosimulations 302, 305, 311, 312, 318
- dissolution 263
- fraction 279
  - biosimulations 303, 309, 319, 325
  - molecular descriptors-based models 303
  - plasma profiles 319
- intestine 118, 121, 121, 181, 195, 205
- pharmacokinetic models 310

- Plá-Delfina and Moreno model 306
- post-membrane predictions 282
- preclinical evaluations 226, 228, 229, 243
- pre-membrane prediction 280
- quotient (AQ) 239
- surface kinetics 162
- absorption, distribution, metabolism and elimination (ADME)
  - absorptive transporters 193
  - biosimulations 307
  - drug discovery 277
  - efflux transporters 213
  - peptide stabilisation 79
  - transport preclinical evaluations 228, 229, 243
- accumulation–time graphs 148
- 2'-acetate erythromycin
  - acid-catalysed degradation 42
  - hydrolysis 42, 42, 57, 57
  - kinetics of decomposition 60
  - pseudo first-order plots 56
- acetic acid 75
- acetylic salicylic acid (ASA) 8
  - Arrhenius plots 64
  - hydrolysis 36, 37
  - ionisation 9
  - ionisation/acidity constants 9, 17
  - kinetics of decomposition 62
  - pH metric titrations 17
  - structure 37
- aciclovir 8, 84
  - bioisosteric replacement 96
  - hydrolysis 38, 41, 55, 60
  - prodrug formation 94
  - specific acid-catalysed hydrolysis 41
  - valaciclovir hydrolysis 38
- acid/base functional groups 8, 20, 23, 24
- acid/base properties
  - amphiphilic drug candidates 12
  - aqueous solubility 7, 18
  - dissolution 260
  - distribution coefficient 24
  - drug candidates 5, 7, 18
  - industrial preformulation, early discovery 103
  - partition properties 23
  - physicochemical
    - characterisation 5, 7, 18
    - solubility–pH profiles 20
- acid-catalysed degradation 42
- acid-catalysed hydrolysis 41
- acid dissociation constants *see* ionisation/acidity constants
- acidity constants *see* ionisation/acidity constants
- active pharmaceutical ingredients (API), definitions 1
- active transport 155, 159
  - carrier-mediated transport
    - kinetics 154, 157
  - dynamic cellular systems 158
  - human transporter classification 175
- acycloxyalkoxy (AOA) 96
- acyl groups
  - acyl carbons 36, 65
  - acyloxyalkoxy-coumarinic-acids 96
  - $\alpha$ -acyloxyalkyl esters 95
  - $\alpha$ -acyloxyalkyl ethers 95
  - $\alpha$ -acyloxyalkyl thioethers 95
  - acyl oxygen protonisation 38, 41
  - hydrolysis 36, 38, 41
  - molecular structures 36, 36
- ADAM *see* Advanced Dissolution, Absorption and Metabolism
- adenosine diphosphate (ADP) 180
- adenosine triphosphate (ATP)
  - carrier-mediated transport
    - kinetics 157
  - human transporter classification 175, 177, 180, 186
  - powered pumps 177, 180, 186
- adenosine triphosphate-binding cassette (ABC) 159
  - efflux transporters 213, 214
  - Gene Ontology 187
  - human transporter classification 186
  - intestine 214

- Pfam database 191
- transport classification system 187
- ADME *see* absorption, distribution, metabolism and elimination
- ADP *see* adenosine diphosphate
- adrenaline 43, 84
- advanced compartmental transit and absorption (ACAT) 312, 314, 315
- Advanced Dissolution, Absorption and Metabolism (ADAM) 314
- affinity 166, 167
- AIC *see* Akaike information criterion
- Akaike information criterion (AIC) 339
- alcohol oxidation 44, 44
- aldehydes 44, 44
- alendronate 73
- E-alkenes 81, 82, 83
- allergies 47
- American Association of Pharmaceutical Scientists (AAPS) 265
- amides 95
  - bioisoteres 79, 80, 81
  - bond lengths and angles 83
  - bond replacement 79
  - hydrolysis 37
  - structure 37
- amidino group in mecillinam 40
- amifostine 84
- amines 8, 15
- amino acids 206
  - absorptive transporters 195, 198, 199
  - carrier-mediated transport kinetics 156
  - deamidation 40
  - epithelial cells 196
  - hydrolysis 38
  - peptide stabilisation 79
  - racemisation 47, 47
  - redox equilibrium 44
  - replacement 80
  - valaciclovir hydrolysis 38
- $\gamma$ -aminobutyric acid 193
- aminomethylene mimetics 81, 82
- amphiphilic drug candidates
  - acid/base properties 12
  - ionisation 12
  - ionisation/acidity constants 12
  - ionised species fraction 22
  - morphine 12
  - neutral species fraction 22
  - partition hypothesis 17
  - pH metric titrations 15
  - solubility in aqueous solution 22
  - species fractions 14, 16
- ampicillin 48, 55, 73, 84
- antioyrine 116
- antiports 154, 155, 157, 179
- AOA *see* acycloxyalkoxy
- API *see* active pharmaceutical ingredients
- apical surface specialisations 115
- apical to basolateral flux 147, 149, 150
- AQ *see* absorption quotient
- aqueous diffusional rate constants 303
- aqueous solubility 5, 7, 14, 18
- aqueous solution 6, 18, 51
- aqueous stability 288
- area under curve (AUC) 284
- Arrhenius equation 62
- Arrhenius plots 64
- ASA *see* acetylic salicylic acid
- ascorbic acid 203
- asparagine 40
- atenolol 140
- ATP *see* adenosine triphosphate
- AUC *see* area under curve
- azathioprine
- azidothymidine (AZT) 96
- AZT *see* azidothymidine
- Baker–Lonsdale dissolution 317
- balsalazide 84
- bambuterol 84
- barrier tissue
  - fluxes 137, 142
  - passive diffusion 135
  - see also* absorption...
- base-centred unit cells 30, 30
- base properties 11
  - see also* acid/base properties
- basket apparatus 265, 266
- basolateral-apical flux 147, 149, 150
- basolateral influx transporters 208

- BCRP *see* breast cancer-resistance proteins
- BCS *see* Biopharmaceutics Classification System
- BDDCS *see* Biopharmaceutics Drug Disposition Classification System
- benaxepilat 84
- benazepril 84
- benzoic acid 75
- BHPH *see* bis-(*p*-hydroxyphenyl)-pyridyl-2-methane
- bile acids 196
- bile formation 218
- bile salt export pumps (BSEP) 215, 219
- binding analysis 165, 168, 169, 238
- bioavailability
  - absorption-enhancement 277
  - absorptive transporters 193
  - alendronate 73
  - ampicillin 73
  - BCS 23, 255, 277, 279
  - BDDCS 255
  - biosimulations 255, 297, 308, 326
  - classification 255
  - cytochrome P450 277, 293
  - decomposition mechanisms 35
  - definitions 1
  - describing 255
  - desmopressin 73
  - dissolution 255, 257
  - dosage form evaluation 297
  - efflux transporters 277
  - erythromycin 73
  - experimental methods 2
  - exsorptive transporters 277
  - food-drug interactions 289
  - P-glycoprotein 277, 293
  - in vitro* dissolution 255, 257, 262
  - in vitro*–*in vivo* correlation 255, 280
  - ivermectin 73
  - kinetics of decomposition 52
  - mathematical models 297
  - membrane permeability 277
  - models 297
  - morphine 73
  - omeprazole 73
  - optimisation
    - bioisoteric replacement 71, 76
    - chemical approaches 6, 71
    - dissolution 6, 71, 72
    - drug candidates 6
    - intestinal peptidases 6
    - Lipinski's rule of five 6, 71
    - oral drug candidates 6
    - peptidases 6
    - peptide stabilisation 6, 76
    - prodrug formation 6, 71, 84
    - salt formation 6, 71, 72, 75, 76
    - solubility rate 6, 71, 72
    - stabilisation 6
  - permeability optimisation 277
  - preclinical investigations 244, 297
  - simulations 297
  - solid-state drug candidates 30
  - solubility 23
  - succinate ester 73
  - transport preclinical evaluations 244
- bioequivalence 278, 286, 294
- biofluids, kinetics of decomposition 52
- bioisosteric replacement
  - amide-based bioisoterics 79, 81
  - bioavailability optimisation 71, 76
  - PEPT1 82, 96
  - peptidomimetics 79
  - valine 96
- biological process gene ontology 183
- biomathematical modelling software 340
- Biopharmaceutics Classification System (BCS)
  - absorption predictions 279
  - application 285
  - BDDCS 292, 293
  - bioavailability 23, 255, 277, 279
  - bioequivalence 278, 286, 294
  - dissolution 278, 286, 288, 290
  - drug development 277
  - drug discovery 277
  - drug disposition 292

- elimination routes 287
- enzyme-transporter interplay 278
- food-drug interactions 289
- formulation strategies 288, 289
- in vitro* dissolution 278, 286
- in vitro*–*in vivo* correlation 290, 294
- in vivo* studies 286
- metabolism 282, 294
- oral bioavailability 279
- oral drug absorption predictions 279
- permeability 277, 278, 282, 285, 287, 292
- pre-membrane absorption 282
- regulatory aspects 286
- solubility 23, 278, 282, 285, 287, 289, 292
- stability 282, 288
- transport preclinical evaluations 245
- Biopharmaceutics Drug Disposition Classification System (BDDCS)
  - BCS 292, 293
  - bioavailability 255, 278, 291
  - permeability 291
  - preclinical evaluations of drug transport 245
  - solubility 291
- bioreversible ester linkages 94
- biosimulations
  - absorption 305, 311, 312, 318
    - fraction 303, 309, 319, 325
    - modelling 302
    - potential 303
  - ACAT 314
  - ADAM 314
  - Akaike information criterion 339
  - bioavailability 255, 297, 308, 326
  - coefficient of correlation 338
  - coefficient of determination 338
  - compartmental models 303, 310, 312, 314, 321
  - computing tools 340
  - convolution 322
  - correlation coefficient 338
  - coupled differential equations 311
  - covariance matrix 336
  - deconvolution 322
  - determination coefficient 338
  - diffusion 303, 305, 318
  - dissolution 302, 311, 313, 315, 325
  - dosage form evaluation
  - dose factors 303
  - dose/solubility ratio 318
  - drug disposition 311
  - extended least squares 331
  - Fisher ratio 339
  - fit factors 337
  - fraction absorbed 303, 309, 319, 325
  - F* test 339
  - Gastroplus 314
  - gradient methods 332
  - Higuchi–Ho model 303
  - information matrix 336
  - in silico* screening 301, 302
  - in vitro* data 301
  - in vitro* dissolution 315
  - in vitro*–*in vivo* correlation 319
  - in vivo* data 301
  - iterations 332
  - least squares 330, 331
  - linear regressions 301, 330
  - link functions 325
  - lipophilicity 302, 304, 305
  - mass balance 302, 308, 321, 322, 324, 328
  - mathematical models 299, 317, 340
  - Michaelis–Menten equation 333
  - molecular descriptors-based models 303
  - Nelder–Mead algorithm 333
  - non-linear regression 301, 332
  - numerical methods 332
  - objective functions 330
  - oral absorption modelling 302
  - passive diffusion 305

- pH 302, 303, 313
  - pharmacokinetics modelling
    - software 340
  - pH-partition theory 303
  - physicochemical characteristics 302
  - physiologically based custom-designed software 340
  - physiological variables 302
  - Plá-Delfina and Moreno model 305
  - plasma profiles 318
  - polydisperse particle dissolution 316
  - preclinical investigations 301
  - quantitative structure–
    - bioavailability 308
  - release modelling 315
  - residual plots 338
  - scientific computing tools 340
  - simplex method 333
  - Snedecor's *F* test 339
  - software packages 339, 340
  - solubility 302, 303, 313, 318
  - standard error of estimation 336
  - time-dependent diffusion 318
  - time-dependent models 310
  - time-independent model 308
  - toxicokinetic software 340
  - transit times 302, 312
  - weighted least squares 331
- biotransformation 288
- bisacodyl 84
- Bjerrum difference plots
  - ephedrine 15
  - monoprotic bases 15
  - morphine 26, 26
  - pH metric titrations 15
  - solubility–pH profiles 20
- blood
  - blood–brain barrier 221, 126, 127, 128,
  - blood–retinal barrier 129
  - concentration curves 284
  - flow 302
  - monoprotic bases 12
- body-centred unit cells 30, 30
- bond lengths and angles 83
- boundary layer thickness 262
- bovine serum albumin (BSA) 238
- brain 126, 127
  - blood–brain barrier 126, 127, 128, 221
  - efflux transporters 221, 221
  - intracellular enzymes 221
- breast cancer-resistance proteins (BCRP) 215, 217
- Brøndsted–Bjerrum equation 64
- Brøndsted–Lowry acids 7
- Brøndsted–Lowry bases 7
- BSA *see* bovine serum albumin
- BSEP *see* bile salt export pumps
- buffers 52, 66, 67, 269
- buprenorphine
  - distribution 16
  - ionisation 15
  - pH metric titrations 15
  - solubility in aqueous solution 22
  - solubility–pH profiles 22, 22
  - species distribution 16
- CA *see* coumarinic acid
- Caco-2 cell models
  - flux ratios 150
  - permeability 166, 140, 147, 149
  - transporter interaction screening 239, 240
  - transport preclinical evaluations 230, 232, 239, 240
- calibration curves 299
- candesartan 84
- capillary electrophoresis 230
- carba ethylene 81
- carbamates 95
- carbimazole 84
- carbonate esters 95
- carbon hydrogen nitrogen
  - microanalysis 108
- carboxylic acid 8, 20, 24, 36
- carboxyls
  - hydrolysis 35, 36
  - structures 36, 37
  - water-catalysed reactions 35
- carriers
  - active transporters 154, 157
  - adsorption surfaces 162

- carrier-mediated transport
    - kinetics 153
      - antiports 154, 157
      - binding analysis 165, 168, 169
      - carrier classification 154
      - carrier functions 154
      - competitive inhibitors 165
      - compound-transporter interactions 164
    - dynamic cellular systems 158, 168
    - efflux transporters 158
    - electrochemical gradients 156
    - enzymes 160, 162
    - flux 160
    - identification of carrier type 160
    - inhibitors 164, 165, 168
    - investigation methods 171
    - ion concentration 154
    - Langmuir equation 162
    - mathematics 160
    - maximal velocity 162
    - measurements 171, 172
    - mechanisms 154
    - Michaelis–Menten constant 163
    - Michaelis–Menten equation 160, 162
    - mixed kinetics 169
    - multiple carriers 169, 170
    - non-competitive inhibitors 169
    - one directional transport 155
    - passive diffusion 169
    - peptide transporters 158, 167, 172
    - rate constants 161
    - saturable transporter kinetics 160
    - steady-state conditions 160
    - study methods 171
    - substrate adsorption surfaces 162
    - substrate-enzyme reactions 160
      - substrates 154, 155, 164
      - symports 154, 156, 158, 167
      - translocation 156
      - transportates 164
      - uncompetitive inhibitors 168
      - uniports 154, 155
        - velocity 160, 162, 166
  - classification 154, 175, 177
  - functions 154
  - human transporter classification 175, 177
- CAT *see* compartmental transit and absorption
- catalysts, hydrolysis 35, 39
- CBER *see* Center for Biologics Evaluation and Research
- CCK *see* cholecystokinin
- CDER *see* Center for Drug Evaluation and Research
- cefuroxime axetil 84
- cell cultures 232
- cell layers 115, 116
- cell shape 115, 116
- cellular component gene ontology 183
- Center for Biologics Evaluation and Research (CBER) 71
- Center for Drug Evaluation and Research (CDER) 71
- central nervous system (CNS) 128, 193
- channels
  - facilitated diffusion 178
  - human transporter classification 175, 177
- charged amino acids 198, 198, 199
- charged solutes 144, 145
- chemical approaches to bioavailability 6, 71
- Chinese hamster ovary (CHO) 213
- chloramphenicol 84
- CHO *see* Chinese hamster ovary
- cholecystokinin (CCK) 209
- chromatography 230
- ciclosporin 77
- cilia 115
- cimetidine 292
- cis-trans* isomerisation 46, 57
- citric acid 75
- CL *see* clearance

- classification
  - bioavailability 255
  - drug substances 2
  - epithelial morphology 115
  - see also* Biopharmaceutics Classification System; Biopharmaceutics Drug Disposition Classification System; human transporter...
- clearance (CL) 283
- cleavage 76, 78
- clinical studies, industrial
  - preformulation 101
- clopidogrel 84
- CNS *see* central nervous system
- CNT *see* concentrative nucleoside transporters
- coefficient of correlation 338
- coefficient of determination 338
- coefficient of variation 331
- colchicine-resistant cells 213
- colistimethate 84
- Collander relationship 304
- colon 118, 123
- compartmental models
  - biosimulations 303, 310, 312, 314, 321
  - flux measurements 138
- compartmental transit and absorption (CAT) 312, 314, 315
- compatibility issues 111
- compendial dissolution media 269
- competitive inhibitors 165, 166
- composition factors 261, 263
- compound diffusion 304
- compound-transporter interactions 164
- computing tools 340
- concentration 337
  - dependence on uptake 168
  - flux 148, 150
  - ion concentration 154
  - kinetics of decomposition 52, 54, 57
  - rate of reaction 337
  - residuals 337
  - velocity dependence 163
- concentration gradients 137
- concentration profiles 324
- concentrative nucleoside transporters (CNT) 159, 203
- conjunctival epithelium 129
- consecutive reactions 59
- construction, models/modelling 300
- convergence criterion 333
- convolution 322, 324, 325
- cornea 129
- correlation
  - absorption–lipophilicity 304, 306
  - coefficient 338
  - transport preclinical evaluations 230, 238
  - see also in vitro–in vivo* correlation
- coumarinic acid (CA) 96
- coupled differential equations 311
- covariance matrix 336
- crystallinity 105, 302
- crystals
  - biosimulations 302
  - lattices 29, 29
  - solid-state characterisation 29
- cubic lattice structures 29, 29
- CV *see* coefficient of variation
- cycloguanil 84
- CYP *see* cytochrome P
- cytochrome P (CYP) 68
- cytochrome P450 213, 214, 242, 277, 293
- DADLE (opioid peptides) 96, 97
- databases
  - absorptive transporters 194
  - human transporter classification 183, 186, 191
- deamidation 40
- decision trees 240, 241
- decomposition kinetics 6, 51
  - see also* kinetics...
- decomposition mechanisms
  - drug candidates 5, 35
  - hydrolysis 35
  - non-oxidative photolytic degradation 46
  - oxidation 43



- physicochemical
    - characterisation 5, 35
    - polymerisation 47
    - racemisation 47
- deconvolution 322, 324, 325
- degradation, 2'-acetate erythromycin 56
- dependent variables, mathematical models 299, 337
- dephosphorylated aminofostine 84
- depth, unit cells 29
- dermis structures, skin 125, 126
- desmopressin 73, 77
- determination coefficient 338
- deterministic models 299
- development
  - BCS 277
  - industrial preformulation 101, 102, 106
- diclofenac 20, 24, 25
- differential equations/models 299, 311
- differential scanning calorimetry (DSC) 106, 110
- diffusion/diffusivity 143, 143
  - biosimulations 303, 305, 318
  - coefficient 135
  - convection controlled models 259
  - dissolution 262, 316
  - layer model 259
  - rate constants 303
- digestion 118
- dihydroriboflavin 45
- dihydroxyethylene 81
- dimensions, unit cells 29
- dimerisation 55
- 5'-O-dipeptide ester 96
- dipeptides 96, 156, 158, 179, 195, 199
- dipivefrine 84
- direct measurements, transport kinetics 172
- disposition 292, 311
  - see also* Biopharmaceutics Drug Disposition Classification System
- dissociation 76
- dissolution 259
  - absorption 263
  - absorption/pharmacokinetic model 310
  - acid/base properties 260
  - Baker–Lonsdale dissolution 317
  - basket apparatus 265
  - BCS 278, 286, 288, 290
  - bioavailability 6, 71, 72, 255, 257
  - biorelevant media
  - biosimulations 302, 311, 313, 315, 325
  - buffer solutions 269
  - compendial media 269
  - composition factors 261, 263
  - diffusion layer model 259
  - equipment 265, 266
  - film theory 259
  - first-order dissolution 299, 317
  - flow-through equipment 265, 267
  - gastric fluids
  - gastrointestinal tissue 121
  - gastrointestinal tract 262, 336
  - Gompertz dissolution 317
  - Higuchi dissolution 317
  - Hixon–Crowell dissolution 317
  - Hopfenberg dissolution 317
  - intestinal fluids
  - intrinsic dissolution equipment 265, 268
  - in vitro–in vivo* correlation 290
  - Korsmeyer–Peppas dissolution 317
  - mathematical models 317
  - mechanism theories 258
  - media 269, 270, 271
  - Monte Carlo simulations 318
  - Noyes–Whitney equation 259, 260, 262, 316, 336
  - paddle apparatus 265
  - particle size 261
  - pH 260, 263
  - physicochemical characteristics 260
  - physicochemical properties 262, 336
  - physiological conditions 262, 336

- pre-membrane absorption
  - prediction 280
  - rate constants 259
  - release process modelling 318
  - residence times 263
  - solid-state drug candidates 30
  - solubility 23, 260, 262, 316
  - stomach
    - surface area 261, 316
    - surface tension 263
    - surfactants 261, 263
    - volume factors 261, 262
  - Weibull dissolution 316, 317
- distribution 7
  - buprenorphine 16
  - ephedrine 15
  - pH profile 25, 27
- distribution coefficient 24
  - diclofenac 20, 24
  - industrial preformulation 105
  - monoprotic acids 24
  - monoprotic bases 24
  - morphine 27
  - propranolol 25
- disulfiram 84
- disulphides 95
- DMPK *see* drug metabolism and pharmacokinetic properties
- dosage form evaluation 297
- dose factors 303
- dose/solubility ratio 318
- driving force 154, 156, 157
- drug absorption modelling 302
- drug candidates
  - absorption barrier structure and function 115
  - acid/base properties 5, 7
  - aqueous solubility 5, 7
  - base properties 11
  - bioavailability optimisation 6, 71
  - chemical stability 18
  - decomposition kinetics 6
  - decomposition mechanisms 5, 35
  - definitions 1
  - distribution 7
  - industrial preformulation 6
  - lipophilicity 5
  - membrane transport 113
  - partition properties 23
  - passive diffusion 135
  - physicochemical
    - characterisation 5
    - solid-state properties 5, 7, 29
    - solubility 5, 7, 18
    - total concentration 9
- drug discovery 228, 229, 277
- drug disposition 292, 293, 311
  - see also* Biopharmaceutics Drug Disposition Classification System
- drug–drug interactions 231, 284
- drug excretion 213
- drug metabolism and pharmacokinetic (DMPK) properties 277
- drug product 2
- drug release modelling, biosimulations 315
- drug stability 5
- drug substances
  - classification 2
  - decomposition kinetics 6
  - definitions 1
- drug transport
  - delivery impacts 205
  - delivery importance 204
  - drug discovery 228
  - epithelial membrane 227
  - see also* preclinical evaluation...
- DSC *see* differential scanning calorimetry
- DVS *see* dynamic vapour sorption
- dynamic cellular systems 158, 168
- dynamic mathematical models 299
- dynamic vapour sorption (DVS) 106
- early development 101, 102, 106
- early discovery 101, 102, 228, 229
- efflux ratio (ER) 239
- efflux transporters 215
  - ATP-binding cassette 213, 214
  - BDDCS 291
  - bile salt export pumps 219
  - bioavailability 277
  - blood–brain barrier 221
  - brain 221

- breast cancer-resistance proteins 215, 217
- carrier-mediated transport
  - kinetics 158
- endothelial cells 221
- epithelial tissue 214, 217, 218, 219
- intestine 214, 216, 217
- kidney 219, 220
- liver 217, 218
- membrane transport 158, 213
- metabolism 213
- multidrug resistance 213, 214, 219
- multidrug resistance-associated transport proteins 214, 217, 220
- electrical fields 145
- electrical potential 144, 145
- electrochemical gradients 156, 157
- electrolytes 64
- electron distribution 76
- electron donors 45
- electron pairs 36, 40
- electrophoresis 230
- elimination 287, 291, 321
- EMA *see* European Medicines Agency
- enalapril 84
- endothelial cells 126, 127, 221
- ENT *see* equilibrative nucleoside transporter 122
- enterocytes 122
- enthalpy 110
- enzymes
  - commission numbers 76, 78
  - efflux transporters 214
  - hydrolytic cleavage 76, 78
  - intestine 216
  - kinetics of decomposition 52, 67
  - liver 218
  - transporter interplay 278
  - transport preclinical evaluations 242
- ephedrine
  - Bjerrum difference plots 15, 15
  - ionisation 11, 17
  - ionisation/acidity constants 11, 15, 17
  - ionisation/base constant 11
  - neutralisation 18
  - pH metric titrations 17
- epidermis structures, skin 125, 126
- epinephrine (adrenaline) 43, 84
- epithelial cells 117, 196
- epithelial classifications 116
- epithelial membrane 227
- epithelial morphology 115, 116
  - brain 126
  - eye 129
  - gastrointestinal tissue barriers 118
  - respiratory tract 123
  - skin 125
- epithelial tissue 214, 217, 218, 219
- equilibrative nucleoside transporter (ENT) 203
- equilibrium potentials 154
- equipment, dissolution 265, 266
- ER *see* efflux ratio
- error predictions 326
- erythromycin 73, 84
  - see also* 2'-acetate erythromycin
- esomeprazole 84
- esters 37, 95
  - hydrolysis 38, 39, 55, 60, 65, 66, 93
  - hydrolytic acyl transfers 38
  - linkages 93
- European Medicines Agency (EMA) 2
- European Pharmacopeia (Ph Eur), solubility 18, 18
- excretion, efflux transporters 213
- ExPASy server 183
- experimental methods 2
  - condition optimisation 238
  - ionisation/acidity constants 14
- exsorption transporters 277
- extended least squares 331
- ex vivo* models 234
- eye 129, 130
- eye drops 130
- eyelids 129
- FA *see* fraction absorbed
- face-centred unit cells 30, 30
- facilitated diffusion 178, 179
- famciclovir 84

- fasted-state simulated gastric fluid  
 (FaSSGF) 271, 271  
 fasted-state simulated intestinal fluid  
 (FaSSIF) 271, 272  
 FBP *see* folate-binding protein  
 FDA *see* Food and Drug  
 Administration  
 fed-state simulated gastric fluid  
 (FeSSGF) 258, 271  
 fed-state simulated intestinal fluid  
 FeSSIF) 271  
 Fick's law 136  
 film theory 259  
 FIP *see* International Pharmaceutical  
 Federation  
 first-order dissolution 299, 317  
 first-order kinetics 52, 57  
 Fisher ratio 339  
 flip-flop 321  
 flow-through equipment 265, 266, 267  
 fluoroalkenes 81, 82  
 fluoroquinolones 303, 304  
 5-fluorouracil (5-FU) 8, 76  
 (Z)-flupentixol 84  
 fluphenazine 84  
 flurbiprofen 19, 20  
 flux 135, 136  
     barrier tissue 137, 142  
     Caco-2 cell models 147, 149  
     carrier-mediated transport  
     kinetics 160  
     charged solutes 144, 145  
     compartmental models 138  
     concentration values 148, 150  
     flux-time graphs 148  
     ratios 145, 150  
     saturable transport 162  
     unstirred layers 141  
 folate-binding protein (FBP) 204  
 folding 121  
 Food and Drug Administration (FDA)  
 2  
 food-drug interactions 289  
 food effects 289, 291  
 formatted protein sequences 183  
 formulation  
     BCS 288, 289  
     biosimulations 302  
     decomposition mechanisms 35  
     kinetics of decomposition 52  
 fosinopril 84  
 fosphenytoin 84  
 fractal kinetics 318  
 fraction absorbed (FA) 303, 309, 319,  
 325  
 free-radical transfers 43  
*F* test 339  
 5-FU *see* 5-fluorouracil  
 full development 101, 102, 111  
  
 GABA *see*  $\gamma$ -aminobutyric acid  
 $\gamma$ -aminobutyric acid (GABA) 193  
 ganaciclovir 84, 96  
 gas exchange 124  
 gastric emptying 290, 302  
 gastric fluids 12, 271, 271  
 gastrointestinal tissue 118, 121  
 gastrointestinal therapeutic system  
 (GITS) 311  
 gastrointestinal tract (GI) 118, 119,  
 262, 336  
 Gastroplus 314  
 Gauss-Newton algorithm 332  
 Gene Ontology (GO) 183, 185, 187  
 general solubility equation (GSE) 28  
 genes 177, 183, 185, 207  
 GI *see* gastrointestinal tract  
 GITS *see* gastrointestinal therapeutic  
 system  
 D-Glu[1-(2-hydroxyethyl)thymine]Ala  
 62  
 Glu(aciclovir)-Sar 41, 62, 94  
 glucose transporters (GLUTs) 155,  
 158, 201  
 Glu(hydroxyethylimine)-Sar 94  
 Glu(OBzl)-Sar 65  
 L-glutamate transporters 193  
 glutathione-S-transferases (GSTs) 213  
 GLUTs *see* glucose transporters  
 P-glycoprotein (P-gp) 186, 213, 214,  
 240, 277, 293, 293  
 GO *see* Gene Ontology  
 Gompertz dissolution 317  
 gradient methods 332  
 GSE *see* general solubility equation  
 GSTs *see* glutathione-S-transferases

- half lives 51, 53, 55, 57, 58, 59
- haloperidol 84
- HATs *see* heteromeric amino acid transporters
- height, unit cells 29
- Henderson–Hasselbalch equation 11
- heparin 277
- hepatic intrinsic clearance 284
- hepatocytes 235
- heteromeric amino acid transporters (HATs) 198
- hexagonal lattice structures 29, 29
- hexoses 196, 201, 201
- HGNC *see* Human Genome Nomenclature Committee
- hidden Markov models (HMMs) 186
- high-pressure liquid chromatography (HPLC) 104
- high-throughput screening (HTS)
  - criteria 129
- Higuchi dissolution 303, 317
- Hixon–Crowell dissolution 317, 317
- HMIT *see* H<sup>+</sup>-*myo*-inositol 317
- HMMs *see* hidden Markov models
- H<sup>+</sup>-*myo*-inositol (HMIT) 201
- Hopfenberg dissolution 317
- HPLC *see* high-pressure liquid chromatography
- HSA *see* human serum albumin
- HTS *see* high-throughput screening criteria
- HUGO *see* Human Genome Organization
- human colon carcinoma cells
  - see* Caco-2 cell models
- Human Genome Nomenclature Committee (HGNC) 183, 185
- Human Genome Organization (HUGO) symbols 185
- human serum albumin (HSA) 238
- human transporter classification 175
  - active transport 175
  - adenosine triphosphate 175, 177, 180, 186
  - adenosine triphosphate-binding cassette 186
  - antiporters 179
  - ATP-powered pumps 177, 180, 186
  - carriers 175, 177
  - channels 175, 177
  - databases 183, 186, 191
  - diffusion 178
  - facilitated diffusion 178
  - Gene Ontology 183, 187
  - genes 177, 183, 185
  - Human Genome Nomenclature Committee 183, 185
  - Human Genome Organization 185
  - Internet 183, 185
  - passive transport 175
  - peptide transporters 179, 186
  - Pfam database 183, 186, 191
  - primary active transport 180
  - profile hidden Markov models 186
  - proteins 175
  - pumps 180
  - secondary active transport 179
  - solute carrier family 185, 186, 187, 191
  - symporters 179
  - transport classification system 180, 185, 187
  - transport mechanisms 177, 186
- hydrochloric acid 75
- hydrogen bond acceptors/donors 71
- hydrogen bonding capacity 76, 307, 307
- hydrolysis
  - 2'-acetate erythromycin 42, 42, 57, 57
  - acetylic salicylic acid 36, 37, 64
  - aciclovir 38, 41, 55, 60
  - acyl carbons 36
  - acyl groups 36, 38, 41
  - acyl oxygen protonisation 38, 41
  - amides 37
  - amino acids 38
  - carboxyls 35, 36
  - catalysts 35, 39
  - decomposition mechanisms 35
  - drug stability 5
  - electron pairs 36, 40

- esters 38, 39, 55, 60, 65, 66, 93
- Glu(aciclovir)-Sar 41
- intramolecular nucleophilic attack 40
- ionic strength 64
- kinetics of decomposition 55
- nucleophilic attack 36, 40
- prodrug candidates 35, 38
- two-electron transfer 35
- valaciclovir 38, 55, 60
- valine 38, 41, 55, 60
- water-catalysed reactions 35, 63
- hydrolytic acyl transfers 38
- hydrolytic cleavage 76, 78
- hydrolytic degradation 72
- hydrophilicity 76
- hydrophilic nutrients 154
- hydroxyethylene 81
- hydroxyethylmine 94
- bis*-(*p*-hydroxyphenyl)-pyridyl-2-methane (BHPH) 84
- hygroscopicity 106
- hypodermis 125
- IAMS *see* immobilised phospholipids onto a silica surface
- ibuprofen dissolution 316, 318
- identification, carrier-mediated transport kinetics 160
- IF *see* intrinsic factor
- imides 37
- immediate release (IR) 264, 325
- immobilised phospholipids onto a silica surface (IAMS) 230
- implicit mathematical models 299
- indirect measurements, transport kinetics 172
- industrial preformulation
  - acid/base properties 103
  - compatibility issues 111
  - crystallinity 105
  - development 101, 102, 106
  - distribution coefficient 105
  - drug candidates 6
  - DSC thermograms 106, 110
  - early development 101, 106
  - early discovery 101, 102
  - enthalpy 110
  - full development 101, 111
  - hygroscopicity 106
  - ionisation/acidity constants 104
  - late discovery 101, 105
  - lead optimisation 101, 104
  - lipophilicity 103, 104
  - melting point 106, 110
  - oxalate salts 106
  - physicochemical characterisation 6, 101
  - polymorphism investigations 110
  - ranking 102
  - salt screening 108
  - solubility 103, 105, 109
  - stability 103, 105, 106
  - thermal stability 106, 109
  - thermogravimetric analysis 106, 109
- influx transporters 208
- information matrix 336
- inhibition
  - carrier-mediated transport kinetics 164, 165, 168
  - concentration dependence 168
  - constants 166, 167
  - transporter interaction screening 240
- in silico* screening 301, 302
- in situ* techniques 231, 237
- integrated models 299, 299
- International Pharmaceutical Federation (FIP) 258, 272
- International Union of Biochemistry and Molecular Biology (IUBMB) 180
- intestinal fluids 12, 271, 271
- intestinal motility 302
- intestinal peptidases 6
- intestinal sac method 236
- intestine
  - absorption 118, 121, 195, 205
  - absorptive transporters 195
  - ATP-binding cassette 214
  - biosimulations 271, 302
  - dissolution 271, 271
  - efflux transporters 214, 216, 217
  - enzymes 216
  - peptide transport 200

- perfusions 237
- time dependent biosimulations 312
- intracellular enzymes 216, 218, 221
- intramolecular nucleophilic attack 40
- intrinsic clearance 283
- intrinsic dissolution equipment 265, 268
- intrinsic factor (IF) 204
- intrinsic solubility 19, 28
- inverse problems, models/modelling 300
- investigation methods, transport kinetics 171
- in vitro* clearance 284
- in vitro* data, biosimulations 301
- in vitro* dissolution
  - BCS 278, 286, 290
  - bioavailability 255, 257, 262
  - biosimulations 315
  - media 269
- in vitro* metabolism 52, 67
- in vitro* preclinical evaluations of transport 226, 228, 229, 231, 238, 243
- in vitro* release 52, 67
- in vitro*–*in vivo* correlation (IVIVC) 320
  - BCS 290, 294
  - bioavailability 255, 280
  - biosimulations 319
  - non-linearity 326, 327, 329
  - post-membrane absorption predictions 284
- in vivo* data, biosimulations 301
- in vivo* studies
  - BCS 286
  - preclinical evaluations of drug transport 226, 228, 238, 243
- ion concentration 154, 154
- ionic strength 52, 64, 65
- ionisation
  - acetylic salicylic acid 9, 17
  - acid/base properties of drug candidates 9
  - amphiphilic drug candidates 12
  - buprenorphine 15
  - diclofenac 20, 24
  - ephedrine 11, 17
  - lidocaine 21
  - monoprotic acids 9
  - monoprotic bases 11
  - morphine 26
  - propranolol 25
- ionisation/acidity constants
  - acetylic salicylic acid 9, 17, 17
  - acid/base property characterisation 7
  - amphiphilic drug candidates 12
  - bioisoteric replacement 76
  - biosimulations 302
  - diclofenac 20, 24
  - ephedrine 11, 15, 17
  - experimental determinations 14
  - industrial preformulation, lead optimisation 104
  - monoprotic acids 9
  - monoprotic bases 11
  - morphine 12, 26, 27
  - pH metric titration 14
  - propranolol 25
  - Yasuda–Shedlowski technique 17
- ionisation/base constants 11
- ionised species fraction 11, 12, 19, 20, 22
- IR *see* immediate release
- irreversible consecutive reactions 59
- irreversible reactions
  - first-order kinetics 52
  - kinetics of decomposition 52, 54, 58, 59
  - pseudo first-order kinetics 54, 58, 59
  - pseudo zero-order kinetics 52
  - second-order kinetics 54
- cis*–*trans* isomerisation 46, 57
- iterations 332, 334
- IUBMB *see* International Union of Biochemistry and Molecular Biology
- ivermectin 73
- IVIVC *see in vitro*–*in vivo* correlation
- keratin 115
- ketomethylene 81
- ketone 43

- kidney 195, 208, 219, 220, 233, 239, 240
- kinetic constants, 166
- kinetics
- absorptive transporters 207
  - carrier-mediated transport kinetics 153
  - decomposition 6, 51
    - acetylic salicylic acid 62
    - Arrhenius equation 62
    - biofluids 52
    - Brøndsted–Bjerrum equation 64
    - buffers 52, 66, 67
    - concentration terms 52, 54, 57
    - electrolytes 64
    - enzymes 52, 67
    - excipient 52
    - first-order kinetics 52, 53, 57
    - half lives 51, 53, 55, 57, 58, 59
    - hydrolysis 55
    - in vitro* metabolism 52, 67
    - in vitro* release 52, 67
    - in vitro*–*in vivo* correlation 67
    - ionic strength 52, 64
    - irreversible reactions 52, 54, 58, 59
    - linear plots 53, 55, 58
    - Michaelis–Menten kinetics 51, 67
    - pH 52, 60
    - pseudo first-order kinetics 54, 57, 58, 59
    - pseudo zero-order kinetics 52
    - rate constants 51, 52, 53, 54, 56, 57, 58
    - rate of reaction 52, 53, 54, 57, 58, 59
    - reversible reactions 57
    - second-order kinetics 54
    - shelf lives 51, 53, 55, 57, 58, 59
    - solubility 52
    - temperature 52, 62
  - stability 6, 51
  - transport preclinical evaluations 226, 228
- Korsmeyer–Peppas dissolution 317
- lactams 37, 47, 193
- lactic acid 75
- lactone 84
- Langmuir equation 162
- lansoprazole 84
- Laplace transforms 324, 325
- latanoprost 84
- late discovery 101, 102, 105, 228, 231
- lattices 29, 29
- LC *see* liquid chromatography
- leads
- definitions 1
  - generation (LG) 102, 228
  - optimization (LO) 101, 102, 104, 228
- least squares 330, 331
- LG *see* leads, generation
- licochalcone A 46, 57
- lidocaine 8, 20, 21, 37
- ligands 164
- light, decomposition mechanisms 5
- light-induced oxidation 45
- liquid chromatography (LC) 172
- linearity conditions 324
- linear models 299
- linear plots 53, 55, 58
- linear regressions 301, 330
- link functions 325
- Lipinski's rule of five 6, 71, 129, 129, 281
- lipophilicity
- absorption–lipophilicity correlation 304, 306
  - bioisoteric replacement 76
  - biosimulations 302, 304, 305
  - diclofenac 25
  - drug candidates 5
  - industrial preformulation 103, 104
  - permeability 307
- liver
- absorptive transporters 208
  - efflux transporters 217, 218



- intracellular enzymes 218
- perfusions 237
- LO *see* leads, optimization
- Loo–Riegelman mass balance 322, 323, 324
- lovastatin 84
- lungs 124
- lymecycline 84
  
- Madin-Derby canine kidney cells (MDCK) 233, 239, 240
- maleic acid 75
- mannitol 116
- mass balance 321, 323, 329
  - biosimulations 302, 308, 321, 322, 324, 328
- mass spectroscopy (MS) 172
- mass transport 135
- mathematical models
  - bioavailability 297
  - biosimulations 299, 317
  - dissolution 317
- mathematics of transport kinetics 160
- maximal velocity 162
- MCT *see* monocarboxylate transporter
- MDCK *see* Madin-Derby canine kidney cells
- MDR *see* multidrug resistance
- measurements, transport kinetics 171, 172
- mechanisms of transport kinetics 154
- mecillinam 37, 40, 84
- media composition 238
- media for dissolution 269, 270, 271
- melting point 106, 110
- membrane permeability 277
- membrane transport 113
  - absorption barrier structure and function 115
  - absorptive transporters 193
  - carrier-mediated transport kinetics 153
  - classification of human transporters 175
  - compound diffusion 304
  - diffusion 135
  - efflux transporters 158, 213
  - flux 135
  - human transporter classification 175
  - migration 135
  - passive diffusion 135, 226
  - permeability 135
  - preclinical evaluation 225
- 6-mercaptapurine 84
- mesalazine 84
- mesylic acid 75
- metabolism
  - BCS 282, 294
  - BDDCS 291
  - efflux transporters 213
  - metabolic clearance 284
  - metabolic stability 229, 293
  - transport preclinical evaluations 236, 242
- metabolizing enzymes 214
- methanesulphonic acid 75
- N*-methylation 79, 80
- metiamazole 84
- metronidazole 84
- metoprolol 116, 140, 316
- Michaelis–Menten constant 163
- Michaelis–Menten curves 162
- Michaelis–Menten equation 160, 162, 283, 333
- Michaelis–Menten kinetics 51, 67
- microvilli 121
- migrating motor complex (MMC) C04.A011
- migration 135
- minerals 196
- mixed kinetics 169
- mixing tank models 310
- MMC *see* migrating motor complex
- models/modelling
  - bioavailability 297
  - construction 300
  - definitions 297
- molecular acid/base properties 5, 7
- molecular descriptors-based models 303, 307
- molecular function gene ontology 183
- molecular mass transport 135
- molecular partition 7
- molecular solubility 5, 7

- molecular structures
  - acyl functional groups 36
  - acyl groups 36, 36
  - carboxyl compounds 36
  - carboxyl functional groups 36
- molecular weight 71, 307, 307
- monocarboxylate transporter (MCT) 203
- monoclinic structures 29
- monoprotic acids
  - distribution coefficient 24
  - Henderson–Hasselbalch equation 11
  - intrinsic solubility 19
  - ionisation 9
  - ionisation/acidity constant 9
  - partition coefficient 23
  - pH metric titrations 17
  - solubility 19, 20
  - species fractions 10, 11, 19, 23
- monoprotic bases
  - Bjerrum difference plots 15
  - distribution coefficient 24
  - gastric juices 12
  - intestinal fluids 12
  - ionisation 11
  - ionisation/acidity constant 11
  - ionisation/base constant 11
  - partition coefficient 23
  - pH metric titrations 17
  - solubility 20
  - species fractions 12, 15, 20, 23
- Monte Carlo simulations 318
- morphine 8
  - acid/base property
    - characterisation 12
  - bioavailability 73
  - Bjerrum difference plots 26
  - distribution coefficient 27
  - ionisation 26, 26
  - ionisation/acidity constant 12, 27
  - oxidation 43
- morphine hydrochloride 27
- morphine sulphate 26, 26
- morphology, epithelium 115, 116
- MRP *see* multidrug resistance-associated proteins
- MS *see* mass spectroscopy
- multidrug resistance-associated proteins (MRP) 214, 215, 217, 220, 277
- multidrug resistance (MDR) 213, 214, 215, 219, 240
- multiple carriers 169, 170
- mycophenolate mofetil 84
- nabumetone 84
- Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE) 157
- naphthalenesulphonic acid 75
- napsylic acid 75
- nasal cavity 124
- Nelder–Mead algorithm 333, 336
- Nernst–Planck equation 144
- neutral amino acids 198
- neutralisation, ephedrine 18
- neutral species fraction 10, 12, 19, 20, 22, 23
- NH-acidic structure 8
- NHE *see* Na<sup>+</sup>/H<sup>+</sup> exchanger
- nicotinic acid 203
- non-competitive inhibitors 166, 169
- non-linear models
  - biosimulations 299
  - in vitro*–*in vivo* correlation 326, 327, 329
- non-linear regressions 301, 332
- non-oxidative photolytic degradation 46
- non-photolytic oxidation 43
- non-polar surface area 307
- non-stationary diffusion 143
- non-stationary flux conditions 150
- non-steady state conditions
  - barrier tissue fluxes 142
  - permeability in Caco-2 cells 149
- nose 124
- Noyes–Whitney equation 259, 260, 262, 280, 316, 336
- nucleophilic attack 36, 36, 39, 40, 40, 65
- nucleosides 206
  - absorptive transporters 202
  - epithelial cells 196
  - transport kinetics 156, 202
- numerical methods, biosimulations 332
- nutrients 196

- OAT *see* organic anion transporter
- OATPs *see* organic anion-transporting polypeptides
- OB *see* oral bioavailability
- objective functions (OF), biosimulations 299, 330
- OCT *see* organic cation transporter
- octanol/water partition coefficient 71
- odds function 327, 327
- oesophagus 118, 119
- OF *see* objective functions
- olfactory epithelium 124
- olsalazine 84
- omeprazole 73, 84
- ondansetron 166
- one directional transport 155
- one-electron transfer, oxidation 43
- opioid peptides (DADLE) 96, 97
- oral absorption 279, 302
- oral bioavailability (OB) 6, 71, 76, 193, 279
- oral cavity 118, 119
- oral drug absorption 279, 302
- oral drug bioavailability optimisation 6, 71
- organ-based *ex vivo* models 234
- organic anion and cation transporters 209
- organic anion transporter (OAT) 210
- organic anion-transporting polypeptides (OATPs) 208, 209
- organic cation transporter (OCT) 210
- orthorhombic structures 29, 30, 30
- oxalate salts, early development 106
- oxcarbazepine 84
- oxidation
  - alcohols 44
  - aldehyde 44
  - decomposition mechanisms 43
  - dihydroriboflavin redox equilibrium 45
  - drug stability 5
  - electron donors 45
  - photolytic reactions 43, 45
  - primary alcohols 44, 44
  - riboflavin redox equilibrium 45
- oxomethylene 81
- oxygen, decomposition 5
- oxymethyl modified coumarinic acid-based linkers 96
- paddle apparatus 265, 266
- PAMPA *see* parallel intraluminal membrane permeability approach
- pantaprazole 84
- paracellular diffusion 226, 305
- paracetamol 84
- parallel intraluminal membrane permeability approach (PAMPA) 226, 230
- parallel irreversible reactions 58
- parecoxib 84
- parsimony 339
- partial least squares (PLS) 230
- partial retro-inverso peptides 80
- particle size 261, 302
- partition properties
  - absorption–partition relationships 306
  - acid/base property drug candidates 23
  - drug candidates 23
  - partition coefficient
    - acid/base property characterisation 7
    - amphiphilic drug candidates 17
    - biosimulations 304
    - drug disposition 292
    - Lipinski's rule of five 71
    - monoprotic acids 23
    - monoprotic bases 23
- passive diffusion 135, 175
  - biosimulations 305
  - carrier-mediated transport kinetics 169
  - concentration gradients 137
  - facilitated diffusion 179
  - membrane transport 226
  - molecular mass transport 135
  - permeability coefficient 137
  - preclinical evaluations 229
  - single carrier transport 169
  - stirred layers 137
  - unstirred layers 139, 141
- passive transport 175

- PCA *see* principal component analysis  
 PEG *see* polyethylene glycol  
 penciclovir 84  
 penicillin allergies 47  
 PEPT1 *see* peptide transporters  
 peptidases 6, 76, 78  
 peptides 206
  - absorption-enhancement 277
  - deamidation 40
  - epithelial cells 196
  - oral bioavailability 76
  - racemisation 47
  - stabilisation 6, 76, 78, 79
  - structure 80
  - transport 200
 peptide transporters (PEPT1) 159
  - absorptive transporters 193, 195, 199
  - bioisosteric replacement 82, 96
  - carrier-mediated transport kinetics 158, 167, 172
  - human transporter classification 179, 186
 peptidomimetics 79  
 peptidosulfonamides 80  
 peptidyl phosphonate 80  
 perfusions 128, 235, 237  
 perindopril 84  
 permeability
  - BCS 277, 278, 282, 285, 287, 289, 292
  - BDDCS 291
  - bioavailability 277
  - biosimulations 302
  - Caco-2 cell models 140, 147, 149
  - charged solute fluxes 144
  - cimetidine 292
  - coefficient 137
  - hydrogen bonding capacity 307
  - in vitro*–*in vivo* correlation 290
  - Lipinski's rule of five 71
  - lipophilicity 307
  - membrane transport 135
  - molecular descriptors 303, 307
  - molecular weight 307
  - non-steady state conditions 142
  - polar surface area 307
  - preclinical evaluations 229, 231
  - solubility 84
  - surface area 307
  - surface descriptor computation 229
  - unstirred layers 141
 perphenazine 84  
 Pfam database 183, 186, 191  
 P-gp *see* P-glycoprotein  
 pH
  - acid/base property characterisation 7
  - aqueous solubility, buprenorphine 22
  - biofluids 13, 51
  - biosimulations 302, 303, 313
  - buprenorphine 16, 22
  - diclofenac 25
  - dissolution 260, 263
  - distribution coefficient 24
  - ephedrine Bjerrum difference plots 15
  - flurbiprofen solubility–pH profile 20
  - gastrointestinal segment functional characteristics 121
  - hydrolysis 38
  - kinetics of decomposition 52, 60
  - metric titrations
    - aqueous solubility 14
    - Bjerrum difference plots 15
    - buprenorphine 15
    - ionisation/acidity constants 14
    - Yasuda–Shedlowski technique 17
  - morphine hydrochloride log $D$ –pH profiles 27
  - oxidation 43
  - partition theory 303
  - preclinical evaluations of drug transport 238
  - proton transfer 7
  - rate profiles 60, 62, 66
  - salt formation 72
  - solubility 20, 20, 22, 22, 108, 313
 pharmaceutical formulation properties 262, 336

- pharmacokinetic dissolution/
  - absorption models 310
- pharmacokinetic modelling software 340
- pharmacokinetic property
  - optimisation 277
- pharmacological activity optimisation 277
- pharynx 119
- phenols 8, 15, 43, 44
- phenytoin 84
- Ph Eur *see* European Pharmacopoeia
- phosphate esters 95
- phosphinyl peptidomimetics 80
- phosphoric acid 75
- photolytic reactions 5, 43, 45, 46
- physicochemical characterisation
  - acid/base properties 5, 7
  - bioavailability optimisation 6
  - biosimulations 302
  - chemical approaches to
    - bioavailability 6, 71
  - decomposition kinetics 6, 51
  - decomposition mechanisms 5, 35
  - dissolution 260
  - drug candidates 5
  - industrial preformulation 6, 101
  - kinetics of decomposition 6, 51
- physicochemical parameters 262
- physicochemical properties 230, 262, 336
- physiological conditions 262, 336
- physiologically based custom-designed software 340
- physiological parameters 262, 302
- picmecillinam 84
- pivampillicin 84
- Plá-Delfina and Moreno model 305
- plasma profiles 299, 318, 319
- plasma protein binding 238
- PLS *see* partial least squares
- polar surface area (PSA) 307, 307
- polydisperse particle dissolution 316, 318
- polyethylene glycol (PEG) 77
- polymerisation 47, 48
- polymers 261
- polymorphism investigations 110
- polysorbates 261
- porins 178
- post-absorption 291
- post-membrane predictions 282
- post-prandial stomach simulations
- POT *see* proton-dependent
  - oligopeptide transporter
- potentiometric titrations 14
- precipitate from toluene 110
- preclinical evaluations of drug transport 225, 232
  - absorption 226, 228, 229, 243
  - ADME 228, 229
  - BCS 245
  - BDDCS 245
  - bioavailability 244
  - Caco-2 cell models 230, 232, 239, 240
  - correlation 230, 238
  - cytochrome P450 242
  - drug discovery 228
  - early discovery 228, 229
  - enzymes 242
  - experimental condition
    - optimisation 238
  - ex vivo* models 234
  - in situ* techniques 231, 237
  - in vitro* techniques 226, 228, 229, 231, 238, 243
  - in vivo* kinetic studies 226, 228, 238, 243
  - late discovery 228, 231
  - MDCK cells 233, 239, 240
  - metabolism 236, 242
  - organ-based *ex vivo* models 234
  - perfusions 235, 237
  - permeability 229, 231
  - physicochemical properties 230
  - predictions 226, 243
  - quantitative structure–property relationship 225, 230
  - solubility 229, 238
  - transporter interaction screening 239
- preclinical investigations
  - bioavailability 297
  - biosimulations 301
- preformulation in the industry 6, 101

- pre-membrane prediction 280
- primary active transport 180
- primary alcohols 44, 44
- primary amines 8
- principal component analysis (PCA) 230
- prodrugs
  - bioavailability optimisation 6, 71, 84, 93
  - ester linkages 93
  - formation 6, 71, 84, 93
  - hydrolysis 35, 38
  - kinetics of decomposition 52
  - linkages 93
- proguanil 84
- pro-moiety introduction 84
- propacetamol 84
- proportional odds model 327, 327
- propranolol 25, 26
- protease enzymes 76, 78
- proteins
  - binding 238
  - deamidation 40
  - expression polarity 117
  - human transporter classification 175
  - racemisation 47
  - stabilisation 6
- proton concentration 7
- proton-dependent oligopeptide transporter (POT) 187
- proton-dependent symports 196, 206
- proton oligopeptide cotransporters 156
- proton transfer 7
- PSA *see* polar surface area
- pseudo first-order kinetics 54, 57, 58, 59
- pseudo first-order plots 56
- pseudopeptides 80
- pseudo zero-order kinetics 52
- pumps 157, 177, 180, 186, 215, 219
- purine nucleosides 202
- pyloric sphincter 118, 121
- pyrimidine nucleosides 202
- QSAR *see* quantitative structure–activity relationship
- QSPR *see* quantitative structure–property relationship
- quantitative structure–activity relationship (QSAR) 308
- quantitative structure–property relationship (QSPR) 225, 230
- quantitative structure–bioavailability 308
- quinapril 84
- rabeprazole 84
- racemisation 47, 47
- ramipril 84
- ranitidine 140
- ranking 102
- rate constants
  - biosimulations 303
  - carrier-mediated transport kinetics 161
  - dissolution 259
  - kinetics of decomposition 51, 52, 53, 54, 56, 57, 58
- rate law 166
- rate of reaction
  - concentration 337
  - kinetics of decomposition 52, 53, 54, 57, 58, 59
  - second-order kinetics 54
- reaction-rate-controlled dissolution 259
- rectum 118, 123
- redox equilibrium 44, 45
- reduced folate transporter (RFT) 203
- regulatory aspects, BCS 286
- release process modelling 318
- renal proximal tubule 200
- residence times 121, 263
- residuals 337, 338
- respiratory tract 123
- retro-inverso peptides 79
- reverse-phase HPLC (RP-HPLC) 104
- reversible inhibitors 166
- reversible reactions 57
- RFT *see* reduced folate transporter
- riboflavin 45, 45
- ring-opening hydrolysis 39
- RP-HPLC *see* reverse-phase HPLC

- rule of five 6, 71, 129, 281
- salicylic acid 75
- salt formation 6, 71, 72, 75, 76
- salt screening 108
- sandwich cultures 235
- SAR *see* structure–activity relationship
- saturable transport 160, 162
- scaling factors 326
- scientific computing tools 340
- secondary active transport 179
- secondary amines 8
- second-order kinetics 54
- secretion quotient (SQ) 239
- segment lengths 121
- SGLT *see* sodium-dependent glucose transporters
- shape factors 30, 76
- shelf lives 51, 53, 55, 57, 58, 59
- simple unit cells 30
- simplex method 333, 336
- simulations
  - bioavailability 297
  - definitions 297
  - gastric fluids, dissolution
  - intestinal fluids, dissolution
- simvastatin 84
- single carrier transport 169
- single nucleotide polymorphism (SNP) 207
- size factors 76
- skin 125, 126
- SLC *see* solute carrier family
- slice technique 236
- small intestine 118, 121, 122, 198, 199, 312
- SMCT *see* sodium-coupled transporters
- SMVT *see* sodium-coupled transporters
- Snedecor's *F* test 339
- SNP *see* single nucleotide polymorphism
- sodium-chloride-dependent symports 196, 206
- sodium-coupled transporters (SMCT, SMVT) 203
- sodium-dependent glucose transporters (SGLT) 159
- sodium-dependent symports 196, 206
- sodium lauryl sulphate 261
- sodium salt dissociation 76
- software packages 229, 339, 340
- solid-state characterisation 29
- solid-state limited solubility 28
- solid-state properties 5, 7, 18, 28
- solubility
  - in aqueous solution 18
    - amphoteric drug candidates 22
    - buprenorphine 22
    - flurbiprofen 19
    - monoprotic acids 19
    - monoprotic bases 20
- BCS 23, 278, 282, 285, 287, 289, 292
- BDDCS 291
- bioavailability 23
- biosimulations 302, 303, 313, 318
- dissolution 23, 260, 262, 316
- drug candidates 5, 7
- European Pharmacopoeia 18, 18
- industrial preformulation 103, 105, 109
- kinetics of decomposition 52
- lidocaine 21
- Lipinski's rule of five 71
- pH profiles 20, 20, 22, 22, 108, 313
- prodrug formation 84
- rate 6, 71, 72
- solid-state limited solubility 28
- transport preclinical evaluations 229, 238
- solute carrier family (SLC)
  - absorptive transporters 194, 198, 201, 208
  - epithelial cells 196
  - human transporter classification 185, 186, 187, 191
  - SLC15A1 185, 186, 187, 191, 195
  - uniports 155
- solute carrier transport 293
- solvation 28
- solvent volumes 262
- sorbitan esters 261

- specialisations, epithelial
  - classifications 116
- species fractions 14, 15, 16
- specific acid-catalysed hydrolysis 41
- specific base catalysts 65
- spontaneous decomposition 52
- spontaneous hydrolysis 35, 63, 64
- SQ *see* secretion quotient
- stability
  - BCS 282, 288
  - bioavailability optimisation 6
  - biosimulations 302
  - decomposition kinetics 6, 51
  - decomposition mechanisms 35
  - industrial preformulation 103, 105, 106
  - solubility in aqueous solution 18
- standard error of estimation 336
- static models 299
- statistical multivariate analysis 230
- steady-state conditions 160
- stochastic models 299
- Stokes–Einstein equation 136
- stomach 118, 120, 312
- stratum corneum 126
- structure–activity relationship (SAR) 228
- structures
  - acyl groups 36, 36
  - amide bond isosteres 80
  - carboxyl functional groups 36
  - opioid peptides 96, 97
  - peptides 80
- structure–bioavailability 308
- study methods, transport kinetics 171
- substrates
  - adsorption surfaces 162
  - carrier-mediated transport
    - kinetics 154, 155, 164
  - enzyme reactions 160
  - solubility 18
  - specificity 154, 207
  - translocation 155
- succinate ester 73
- succinic acid 75
- sulphotransferase (SULT) 242
- SULT *see* sulphotransferase
- superqualifiers 102
- surface area 121
  - biosimulations 302, 307
  - dissolution 261, 316 262
  - permeability 307
  - pH in biological media 13
- surface descriptor computation 229
- surface tension 263
- surfactants 261, 263
- Swiss Institute of Bioinformatics
  - BLAST Network service 183
- SwissPfam database 183, 186, 191
- symports 154, 155, 156, 158, 167, 179, 196, 206
- system variables, biosimulations 297
- target identification (TI) 228
- tartaric acid 75
- Taylor’s approximation 332
- TC *see* transporter classification
- TCDB *see* transporter classification database
- TEER *see* transepithelial electrical resistance
- temazolamide 84
- temperature 52, 62
- terbutaline 140, 140
- tertiary amines 8
- tetracycline 84
- tetragonal structures 29
- TGA *see* thermogravimetric analysis
- thalidomide 37
- thermal stability 106, 109
- thermogravimetric analysis (TGA) 106, 109, 110
- thiamine transporter (ThT) 203
- ThT *see* thiamine transporter
- TI *see* target identification
- tight junctions 117, 126
- time
  - accumulation–time graphs 148
  - flux–time graphs 148
  - time-dependent diffusion 318
  - time-dependent mathematical models 299, 310
  - time-independent model 308
- tissue segments 205
- tissue slices 236
- titrations



- morphine sulphate 26, 26
- pH metric titrations 14
- solubility–pH profiles 20
- TMS *see* transmembrane segments
- toxicokinetic software 340
- trandolapril 84
- transcellular diffusion 226, 229
- transepithelial electrical resistance (TEER) 126
- transition state mimetics 80
- transit times 263, 302, 312
- translocation 155, 156, 157
- transmembrane segments (TMS), human transporter classification 183
- transport
  - carrier-mediated transport kinetics 153
  - classification system
    - gene ontology 185
    - human transporter classification 180, 185, 187
  - gene ontology 185
  - human transporter classification 180, 185, 187
  - mechanisms 177, 186
  - neutral amino acid transport 198
  - passive diffusion 135
  - rate-controlled dissolution 259
- transportates, kinetics 164
- transporter classification (TC) 180
- transporter classification database (TCDB) 183
- transporter-enzyme interactions 291
- transporter interaction screening 239
- transporter-substrate complex binding 168
- travoprost 84
- triclinic structures 29
- trifluorethylamine 81
- trigonal structures 29
- tripeptides 156, 158, 179, 195, 199
- two-electron transfer 35
- tyrosine 44
  
- UGT *see* uridine diphosphate glucuronosyl transferase
- uncompetitive inhibitors 166, 168
  
- uniports 154, 155, 179, 196
- unit cells 30, 30
  - dimensions 29
  - shape 30
  - solid-state characterisation 29
- unstirred layers 139, 141
- uphill transport 156
- uptake 168
- uptake ratio (UR) 239
- UR *see* uptake ratio
- uridine 203
- uridine diphosphate glucuronosyl transferase (UGT) 242
- US Pharmacopoeia (USP) 257
- Ussing chambers 144, 236, 242
  
- valaciclovir 8
  - absorptive transporters 193
  - bioisosteric replacement 96
  - hydrolysis 38, 55, 60
  - pH-rate profile 62
- valdecoxib 84
- valganciclovir 84, 96
- validation techniques 326
- valine 8
  - bioisosteric replacement 96
  - hydrolysis 38, 41, 55, 60
  - valaciclovir hydrolysis 38
- variance–covariance matrix 336
- velocity 160, 162, 163, 166
- verification techniques 300
- vesicles 234
- villi 121, 122
- vitamins 196, 203, 204
- volume factors 261, 262
  
- Wagner–Nelson method 203, 321, 324
- water-catalysed reactions 35, 63
- Weibull dissolution 316, 317
- weighted least squares 331
- width, unit cells 29
  
- X-ray powder diffraction (XRPD) 105, 108, 109
  
- Yasuda–Shedlowski technique 17
- zuclopentixol 84

